Anti-Activin Deal Benchmarks in Metabolic & Obesity

Median Upfront

$1.0B

Range: $567M - $1.5B

Total Deal Value

$4.9B

Range: $3.2B - $6.6B

Royalty Rate

16.5% - 30%

Tiered up to 34.2%

Dev Milestones

$695M

Range: $471M - $923M

Model Your Deal

Market Analysis

Anti-Activin therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 anti-activin asset in metabolic & obesity is $1.0B, with total deal values reaching $4.9B. Development milestones average $695M, while regulatory milestones contribute $849M.

The metabolic & obesity anti-activin landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for anti-activin metabolic & obesity deals range from 16.5% to 30% at the base tier, with tiered escalation reaching 20.5%-34.2% on blockbuster sales. Commercial milestones averaging $2.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a anti-activin metabolic & obesity licensing deal?

Based on our analysis, Phase 2 anti-activin licensing deals in metabolic & obesity average $1.0B in upfront payments, with a range of $567M to $1.5B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for anti-activin metabolic & obesity transactions?

The median total deal value for Phase 2 anti-activin assets in metabolic & obesity is $4.9B, ranging from $3.2B to $6.6B. This includes development milestones ($695M), regulatory milestones ($849M), and commercial milestones ($2.3B).

What royalty rates are standard for anti-activin deals in metabolic & obesity?

Base royalty rates for anti-activin metabolic & obesity transactions range from 16.5% to 30%, with tiered escalations reaching 20.5%-34.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in anti-activin metabolic & obesity deals?

Anti-Activin metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($695M) make up the largest share, followed by commercial milestones ($2.3B) and regulatory milestones ($849M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included